Fourth Quarter & Full Year 2022 Financial & Business Update
Developing PADCEV into a Bladder Cancer Blockbuster and
Pursuing Other Solid Tumors
Advancing into 1L mUC with Keytruda, Priority
Review granted with April 21, 2023 PDUFA¹
EV-103 Cohort K Data Presented at ESMO 2022²
100
80-
60-
40- 97.1% of assessable patients had tumor reduction
PD-L1 Score
High (CPS ≥10)
■Low (CPS <10)
Not evaluable
Best Overall Response
Confirmed CR/PR
Tumor Size (% Change from Baseline)
-20
-40
-60-
-80-
20
888
-100-
EV + P (n=69)
64.5%³ CORR by BICR and rapid responses; median DOR not
reached; responses seen regardless of PDL-1 expression
Seagen Collaboration with
astellas
PADCEV
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials
Current U.S. SOC in post-
platinum / PD-(L)1
metastatic urothelial
cancer
Enabling potential global registrations with 1L
mUC phase 3 trial EV-302
Patient enrollment complete, with topline data estimated by
YE232
Evaluating Keytruda combination for MIBC
with EV-303 & EV-304 Phase 3 trials
•
Enrolling in cisplatin-eligible and ineligible patients in
curative setting
Exploring NMIBC and other solid tumors with
trials EV-104 and EV-202, respectively
Initial EV-104 and EV-202 data expected 1H 2023
1 In patients ineligible for cisplatin-based chemotherapy; not currently approved for use; 2 Rosenberg, et al, ESMO 2022; 3 Based on study assumptions; additional
study details can be found at clinicaltrials.gov; refer to PADCEV USPI for complete safety information, including a BOXED WARNING for Serious Skin Reactions
23View entire presentation